Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046807 | 0.89 | SCD (0.47) | MMP13GAAHPGDMAPK1ALDH1A1 | |
| SCHEMBL3042184 | 0.81 | SCD (0.60) | TSHRMMP13GAAHPGDALDH1A1 | |
| SCHEMBL12195636 | 0.79 | TSHR (0.62) | TSHRMMP13GAALMNAHPGD | |
| SCHEMBL3051517 | 0.77 | HPGD (0.57) | TSHRMMP13GAALMNAHPGD | |
| SCHEMBL27785697 | 0.77 | HPGD (0.48) | TSHRLMNAHPGDMAPK1ALDH1A1 | |
| SCHEMBL3048776 | 0.76 | SCD (0.53) | TSHRGAALMNAHPGDRECQL | |
| SCHEMBL3456455 | 0.75 | LMNA (0.47) | TSHRLMNAHPGDRECQLMAPK1 | |
| SCHEMBL3043695 | 0.75 | HPGD (0.54) | TSHRMMP13GAALMNAHPGD | |
| SCHEMBL14162241 | 0.74 | SCD (0.45) | TSHRMMP13GAAHPGDALDH1A1 | |
| SCHEMBL15421497 | 0.71 | NAMPT (0.62) | TSHRMMP13GAALMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101595105-B | 2-substituted 5-membered heterocycles as SCD inhibitors | NOVARTIS AG | 2013-01-23 | — | — | CN | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101595105-A | 5 membered heterocyclic compounds that replace as the 2-of SCD inhibitor | NOVARTIS AG XENON PHARMACEUTIC (CH) | 2009-12-02 | — | — | CN | disclosed |
| EP-2121671-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074835-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074835-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029722-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | TSHR 4191/4885MMP13 1303/4885GAA 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.